Can you take Plasminogen, human with Ticagrelor?
1 drug interaction and 7 additional warnings found for the following 2 drugs:
- plasminogen, human
- ticagrelor
Drug interactions
Major drug interactions
Major:
ticagrelor plasminogen, human
Applies to: ticagrelor and plasminogen, human
Using plasminogen, human together with ticagrelor may increase the risk of bleeding.
Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications.
You should seek immediate medical attention if you experience any unusual bleeding or bruising or have other signs and symptoms of bleeding such as:
- dizziness
- lightheadedness
- red or black, tarry stools
- coughing up or vomiting fresh or dried blood that looks like coffee grounds
- severe headache
- weakness
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
ticagrelor Food/Lifestyle
Applies to: ticagrelor
Grapefruit juice may increase the blood levels of ticagrelor and may increase the risk of bleeding complications.
Talk to your doctor if you have any questions or concerns.
Call your doctor promptly if you experience any unusual bleeding or bruising, swelling, vomiting, blood in your urine or stools, headache, dizziness, or weakness during treatment.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
6 potential interactions Applies to: 6 conditions, including Peptic Ulcer, Hemodialysis, Liver Disease, Bleeding Disorder, and Sinus Node Dysfunction.
Bleeding Disorder
Major:
ticagrelor
Ticagrelor has a major potential interaction with Bleeding Disorder.
Ticagrelor is contraindicated in patients with active pathological bleeding, such as peptic ulcer or intracranial hemorrhage.
Hemodialysis
Moderate:
ticagrelor
Ticagrelor has a moderate potential interaction with Hemodialysis.
No dosage adjustment is needed in patients with renal impairment. Patients receiving dialysis have not been studied, close monitoring is recommended.
Liver Disease
Major:
ticagrelor
Ticagrelor has a major potential interaction with Liver Disease.
Ticagrelor is metabolized by the liver. The use of ticagrelor should be avoided in patients with severe hepatic impairment. Care should be taken in patients with moderate hepatic impairment and it is recommended to consider the risks and benefits of treatment due to the probable increase in exposure to ticagrelor. No dosage adjustment is needed in patients with mild hepatic impairment.
Peptic Ulcer
Major:
ticagrelor
Ticagrelor has a major potential interaction with Peptic Ulcer.
Ticagrelor is contraindicated in patients with active pathological bleeding, such as peptic ulcer or intracranial hemorrhage.
Pulmonary Impairment
Moderate:
ticagrelor
Ticagrelor has a moderate potential interaction with Pulmonary Impairment.
Dyspnea has been reported with the use of ticagrelor. Care should be taken when prescribing this drug to patients that experienced dyspnea. If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to the drug, no specific treatment is required; continue treatment and monitoring without interruption, if possible. In the case of intolerable dyspnea requiring discontinuation, consider prescribing another antiplatelet agent.
Sinus Node Dysfunction
Moderate:
ticagrelor
Ticagrelor has a moderate potential interaction with Sinus Node Dysfunction.
Ticagrelor can cause ventricular pauses. Bradyarrhythmias including AV block have been reported in the postmarketing setting. It is recommended to use care if prescribing this agent to patients with a history of sick sinus syndrome, 2nd or 3rd degree AV block or bradycardia-related syncope not protected by a pacemaker as they may be at increased risk of developing bradyarrhythmias.
Report options
More resources
plasminogen, human
A total of 77 drugs are known to interact with plasminogen, human.
- Plasminogen, human is in the drug class miscellaneous uncategorized agents.
- Plasminogen, human is used to treat Hypoplasminogenemia.
ticagrelor
A total of 550 drugs are known to interact with ticagrelor.
- Ticagrelor is in the drug class platelet aggregation inhibitors.
- Ticagrelor is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.